SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001439222-23-000138
Filing Date
2023-11-02
Accepted
2023-11-02 07:02:21
Documents
14
Period of Report
2023-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agio-20231102.htm   iXBRL 8-K 33211
2 EX-99.1 agio-110223xex991earningsr.htm EX-99.1 64762
6 GRAPHIC image_0.jpg GRAPHIC 58526
  Complete submission text file 0001439222-23-000138.txt   313178

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT agio-20231102.xsd EX-101.SCH 1883
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT agio-20231102_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT agio-20231102_pre.xml EX-101.PRE 12496
8 EXTRACTED XBRL INSTANCE DOCUMENT agio-20231102_htm.xml XML 2720
Mailing Address 88 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 88 SIDNEY STREET CAMBRIDGE MA 02139 617-649-8600
AGIOS PHARMACEUTICALS, INC. (Filer) CIK: 0001439222 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36014 | Film No.: 231370006
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences